Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot
NRx Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops new treatments for the treatment of life-threatening central nervous system disorders and lung diseases. The company is headquartered in Wilmington, Delaware.
52W High
$0.50
52W Low
$0.04
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.64
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
N/A
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
N/A
Ownership
Source: Overview
Insiders (1–5% typical)
0.00%
Institutions (25–75% balanced)
0.00%
Shares Outstanding
0
Float
13,611,100
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-6.25
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-6.83%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Value
N/A
Previous
N/A
Trend
—
Signal Cross
No cross
As of
—